Trial Search Results

Cycled Phototherapy

Cycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (< 750 g BW or <27 weeks GA).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

NICHD Neonatal Research Network

Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Stanford Investigator(s):


  • Device: Phototherapy lights


Phase 3


Inclusion Criteria:

   1. Infants is inborn

   2. Infant is ≤ 750 grams at birth and/or < 27 weeks gestation at birth by best OB

   3. Infant is 12-36 hours of age.

Exclusion Criteria:

   1. Unable to enroll infant by 36 hours of age

   2. Previous phototherapy

   3. Known hemolytic disease

   4. TSB reported as >6.0 mg/dL before 12 hours age

   5. Major anomaly

   6. Overt nonbacterial infection

   7. Infant is likely to expire soon: Limiting or withdrawal of intensive care is being
   recommended to the parents, the parents are requesting withdrawal of care, or the pH
   is < 6.80 or persistent bradycardia with hypoxemia for >2h.

Ages Eligible for Study

22 Weeks - 27 Weeks

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Krisa P. Van Meurs, MD
Not Recruiting